Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women

Abstract

Background: Rilpivirine pharmacokinetics is defined by its absorption, distribution, metabolism, and excretion. Pregnancy can affect these factors by changes in cardiac output, protein binding, volume of distribution, and cytochrome P450 (CYP) 3A4 activity. Rilpivirine is metabolized by CYP3A4. The impact of pregnancy on rilpivirine pharmacokinetics is largely unknown.

Methods: International Maternal Pediatric Adolescent AIDS Clinical Trials P1026s is a multicenter, nonblinded, prospective study evaluating antiretroviral pharmacokinetics in HIV-infected pregnant women that included a cohort receiving rilpivirine 25 mg once daily as part of their combination antiretrovirals for clinical care. Thirty-two women were enrolled in this study. Intensive pharmacokinetic sampling was performed at steady state during the second trimester, the third trimester, and postpartum. Maternal and umbilical cord blood samples were obtained at delivery. Plasma rilpivirine concentration was measured using liquid chromatography-mass spectrometry; lower limit of quantitation was 10 ng/mL.

Results: Median (range) AUC0-24 were 1969 (867-4987, n = 15), 1669 (556-4312, n = 28), and 2387 (188-6736, n = 28) ng·h/mL in the second trimester, the third trimester, and postpartum, respectively (P < 0.05 for either trimester vs postpartum). Median (range) C24 were 63 (37-225, n = 17), 56 (<10-181, n = 30), and 81 (<10-299, n = 28) ng/mL (P < 0.05 for either trimester vs postpartum). High variability in pharmacokinetic parameters was observed between subjects. Median (range) cord blood/maternal concentration ratio was 0.55 (0.3-0.8, n = 21). Delivery HIV-1 RNA was ≤50 copies per milliliter in 70% and ≤400 copies per milliliter in 90% of women. Cmin were significantly lower at 15 visits with detectable HIV-1 RNA compared with 61 visits with undetectable HIV-1 RNA, 29 (<10-93) vs 63 (15-200) ng/mL (P = 0.0001). Cmin was below the protein binding-adjusted EC90 concentration (12.2 ng/mL) at 4 visits in 3 of 31 women (10%).

Conclusions: Rilpivirine exposure is lower during pregnancy compared with postpartum and highly variable. Ninety percent of women had minimum concentrations above the protein binding-adjusted EC90 for rilpivirine.

Conflict of interest statement

Conflicts of Interest: All other co-authors have no conflicts (A.H.T., B.M.B., A.S., J.W., E.V.C., S.K.B., R.K., K.R., K.G., T.R.C., N.C., E.S., D.E.S.).

Figures

Figure 1. Rilpivirine Median Plasma Concentrations Over Time

Second trimester, blue line with diamonds; Third trimester, red line with squares; Postpartum, green line with triangles; Non-pregnant reference population, purple line with x’s. Non-pregnant reference exposure was determined from package insert.[6] Error bars are standard error of the median.

Figure 2. Rilpivirine AUC during Pregnancy and Postpartum

Area under the rilpivirine concentration time curve during the second and third trimesters, and again postpartum. Each line represents a single subject. Dashed line represents subject on concomitant darunavir/ritonavir. P=0.048 for second trimester versus postpartum with the Wilcoxon signed-rank test. P=0.012 for third trimester versus postpartum with the Wilcoxon signed-rank test. P=0.272 for second trimester versus third trimester with the Wilcoxon signed-rank test.

Figure 3. Rilpivirine C24 during Pregnancy and Postpartum

24 hour post-dose rilpivirine concentration during the second and third trimesters, and again postpartum. Each line represents a single subject. Dashed line represents subject on concomitant darunavir/ritonavir. P=0.013 for second trimester versus postpartum with the Wilcoxon signed-rank test. P=0.003 for third trimester versus postpartum with the Wilcoxon signed-rank test. P=0.309 for second trimester versus third trimester with the Wilcoxon signed-rank test.